Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 26:11:791.
doi: 10.3389/fphar.2020.00791. eCollection 2020.

Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?

Mekonnen Sisay  1
Affiliations
Review

Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?

Mekonnen Sisay. Front Pharmacol. .

Abstract

The novel coronavirus strain, severe acute respiratory syndrome coronavirus-2, the causative agent of COVID-19 emerged in Wuhan, China, in December 2019 and is skyrocketing throughout the globe and become a global public health emergency. Despite promising preventive measures being taken, there is no vaccine or drug therapy officially approved to prevent or treat the infection. Everybody is waiting the findings of ongoing clinical trials in various chemical and biological products. This review is specifically aimed to summarize the available evidence and ongoing clinical trials of remdesivir as a potential therapeutic option for COVID-19. Remdesivir is an investigational drug having broad spectrum antiviral activity with its target RNA dependent RNA polymerase. It has not yet been officially approved for Ebola and Coronaviruses. Several studies showed that remdesivir had promising in vitro and in vivo antiviral activities against SARS-CoV-1 and MERS-CoV strains. On the top of this, it exhibited a promising in vitro activity against SARS-CoV-2 strains though there are no published studies that substantiate its activity in vivo until the time of this review. There are few phase 3 randomized double-blind placebo controlled trials on the way to investigate the safety and efficacy of remdesivir. Of which, one completed double blind, placebo controlled trial showed that remdesivir showed faster time to clinical improvement in severe COVID-19 patients compared to placebo though not found statistically significant. In addition, two phase 3 randomized open label clinical trials coordinated by Gilead Sciences are being conducted. In addition, WHO Solidarity trial and INSERM DisCoVeRy trials (randomized open labels) were launched recently.

Keywords: COVID-19; GS-5734; RdRp; SARS-CoV-2; remdesivir.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structure and metabolic conversion of remdesivir.
See this image and copyright information in PMC

References

    1. Agostini M. L., Andres E. L., Sims A. C., Graham R. L., Sheahan T. P., Lu X., et al. (2018). Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio 9, e`1–00218. 10.1128/mBio.00221-18 - DOI - PMC - PubMed
    1. Branswell H. (2020). WHO to launch multinational trial to jumpstart search for coronavirus drugs (World Health Organization; ). Available at: https://www.statnews.com/2020/03/18/who-to-launch-multinational-trial-to... Accessed on 20 March, 2020.
    1. Brown A. J., Won J. J., Graham R. L., Dinnon III K. H., Sims A. C., Feng J. Y., et al. (2019). Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 169, 104541. 10.1016/j.antiviral.2019.104541 - DOI - PMC - PubMed
    1. Cao B., Wang Y., Wen D., Liu W., Jingli W., Fan G., et al. (2020). A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New Engl. J. Med. 10.1056/NEJMoa2001282. 2020. - DOI - PMC - PubMed
    1. Cao B. (2020. a). Mild/Moderate 2019-nCoV Remdesivir RCT, Available at: https://clinicaltrials.gov/ct2/show/NCT04252664 Accessed on 20, March, 2020.